2026-01-26 - Analysis Report
**Report for Amgen Inc. (AMGN)**

### Company Overview
Amgen Inc. is a biotechnology company.

### Return Rate Comparison

* Cumulative Return of Review Stock: **90.93%**
* Cumulative Return of Comparison Stock (S&P 500, VOO): **126.41%**
* Divergence: **-36.00**, Relative Divergence: **34.30%**

The review stock underperformed the comparison stock, with a divergence of -36.00 and a relative divergence of 34.30%.

### Alpha, Beta Analysis

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 20.0% | 16.1% | 8.0% | 1.1 | 104.8B |
| 2017-2019  | 45.0% | 12.1% | 20.0% | 0.9 | 129.8B |
| 2018-2020  | 18.0% | 21.8% | -6.0% | 0.8 | 123.8B |
| 2019-2021  | 15.0% | 21.8% | -50.0% | 0.8 | 121.1B |
| 2020-2022  | 18.0% | 19.4% | 11.0% | 0.6 | 141.4B |
| 2021-2023  | 21.0% | 20.6% | 1.0% | 0.4 | 155.1B |
| 2022-2024  | 15.0% | 21.2% | -15.0% | 0.4 | 140.3B |
| 2023-2025  | 38.0% | 21.3% | -37.0% | 0.5 | 176.2B |

### Recent Stock Price Fluctuations

* Close: **$344.75**
* Last-Market: **-$0.67**
* 5-day SMA: **$339.37**
* 20-day SMA: **$331.73**
* 60-day SMA: **$327.76**

The review stock decreased in the last market day, with a 5-day SMA lower than the 20-day and 60-day SMA.

### RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence

* Market Risk Indicator (MRI): **0.70** (High Investment Recommended)
* RSI: **62.17**
* PPO: **0.54**
* Recent (20 days) relative divergence change: **9.50** (+) (improving)
* 7-day Rank change: **0** (flat)
* 7-day Dynamic Expected Return change: **0.00** (flat)

The hybrid signal is Buy (Cash 0%), and the risk level is Medium.

### Expected Return

* Expected Return (%): **-30.50%** (Expected excess return compared to S&P 500 if invested long-term)

### Recent News & Significant Events

* [2026-01-25] Will 340B Lawsuit Over Drug Discounts Shift Amgen's (AMGN) Access Strategy And Investment Narrative? - [simplywall.st](link)
* [2026-01-25] Whittier Trust Co. Acquires 39,111 Shares of Amgen Inc. $AMGN - [MarketBeat](link)
* [2026-01-22] Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know - [Yahoo Finance](link)
* [2026-01-25] Amgen stock price slips from record close as AMGN heads into earnings and the obesity-drug race - [TechStockÂ²](link)
* [2026-01-22] Amgen stock hits 52-week high at $346.41 - [Investing.com](link)
* [2026-01-23] SA analyst upgrades/downgrades: GE, MSFT, SMCI, AMGN - [Seeking Alpha](link)

### Analyst Opinions

 Analyst Consensus:
* Key: **Buy**
* Mean (1=StrongBuy~5=Sell): **2.41** (~Buy)
* Opinions: **27**
* Target Price (avg/high/low): **331.59 / 425.00 / 180.00**

### Recent Earnings Analysis

| Date | EPS | Revenue |
|---|---:|--|
| 2025-11-05 | 5.98 | 9.56 B$ |
| 2025-08-06 | 2.66 | 9.18 B$ |
| 2025-05-02 | 3.22 | 8.15 B$ |
| 2024-10-31 | 5.27 | 8.50 B$ |

Earnings per share (EPS) was 5.98 in 2025-11-05, and revenue was 9.56B$. 

### Financial Information

#### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

Revenue has been increasing over the past quarters, with a profit margin of 67.75% in the most recent quarter.

#### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

Equity has been increasing over the past quarters, with a return on equity (ROE) of 33.43% in the most recent quarter.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.